Immix Biopharma to Participate in the Jefferies Global Healthcare Conference

Immix Biopharma (NASDAQ:IMMX) will participate in the Jefferies Global Healthcare Conference June 2-4, 2026 in New York.

Rhea-AI Summary

Immix Biopharma (NASDAQ:IMMX) will participate in the Jefferies Global Healthcare Conference June 2-4, 2026 in New York.

The company said it will host one-on-one institutional investor meetings and that a replay link will be posted to its Presentation & Events page on the investor website when available.

Argus Apr 9 session

+11.43% close to close Open Argus

Details

News Market Reaction – IMMX

On Apr 9, the day this news came out, IMMX closed 11.43% above the previous close.

Data tracked by StockTitan Argus for the Apr 9 session.

Market Context

On Apr 9, the day this news came out, the stock closed 11.4% above the previous close. A strong posi...

Analysis

On Apr 9, the day this news came out, the stock closed 11.4% above the previous close. A strong positive reaction aligns with IMMX’s history of responding well to visibility and milestone updates, such as prior gains of 3.37% and 5.28% after key clinical news. However, the company maintains an effective shelf of up to $750,000,000, and has already tapped it via an ATM program, so additional equity issuance has been an ongoing factor. Investors have also reacted positively to past financings, but that pattern may not persist indefinitely.

Key Figures

Conference dates: June 2–4, 2026

Conference dates

June 2–4, 2026

Jefferies Global Healthcare Conference in New York, NY

Historical Context

5 past events · Latest: Mar 30

5 events

1. Mar 30

   Trial enrollment complete

   24h Move

   +5.3%

   Completed enrollment in BLA-enabling NEXICART-2 trial with Q3 2026 topline guided.

2. Mar 03

   Investor conferences

   24h Move

   -2.5%

   Announced participation in two March 2026 institutional investor conferences in Miami Beach.

3. Jan 28

   Breakthrough designation

   24h Move

   +3.4%

   FDA Breakthrough Therapy Designation for NXC-201 based on NEXICART-2 Phase 2 interim data.

4. Dec 09

   Offering closing

   24h Move

   +2.0%

   Closed upsized $100M underwritten offering of common stock and pre-funded warrants.

5. Dec 07

   Offering pricing

   24h Move

   +10.6%

   Priced upsized $100M underwritten equity and pre-funded warrant offering for NXC-201 funding.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY.

The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Jefferies representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.

About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed/refractory AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.

Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Company Contact
irteam@immixbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Immix Biopharma (IMMX) attend the Jefferies Global Healthcare Conference in 2026?

Immix Biopharma will attend the conference June 2-4, 2026 in New York. According to the company, management will be onsite for presentations and one-on-one institutional investor meetings during those dates, and scheduling is handled through Jefferies representatives.

How can investors schedule one-on-one meetings with Immix Biopharma (IMMX) at Jefferies Global Healthcare Conference?

Investors should contact their Jefferies representative to request meetings with Immix Biopharma. According to the company, Jefferies will coordinate institutional one-on-one meeting requests and schedule availability for June 2-4, 2026.

Will Immix Biopharma (IMMX) provide a replay of its Jefferies conference presentation?

Yes, a replay will be posted to Immix Biopharma's investor site when available. According to the company, a link to the replay will appear on the Presentation & Events page under the Investors section after the event.

Where can investors find Immix Biopharma (IMMX) presentation materials after the Jefferies conference?

Presentation materials and the replay will be posted on the company's investor website Presentation & Events page. According to the company, investors should check the Investors section for the replay link and any presentation documents after the event.

What type of meetings will Immix Biopharma (IMMX) hold at the Jefferies Global Healthcare Conference?

Immix Biopharma will host institutional one-on-one investor meetings during the conference. According to the company, these meetings are intended for institutional investors and must be arranged through a Jefferies representative in advance.